Effects of inhaled human insulin on airway lining fluid composition in adults with diabetes

European Respiratory Journal

Volumn 32, Issue 1, 2008, Pages 180-188

  Liu, M C ^a   Riese, R J ^b   Van Gundy, K ^c   Norwood, P ^d   Sullivan, B E ^b   Schwartz, P F ^b   Teeter, J G ^b  

^a JOHNS HOPKINS ASTHMA AND ALLERGY CENTER   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Valley Research   (United States)

Author keywords

Bronchoalveolar lavage; Bronchoscopy; Exubera ; Glycaemic control; Pulmonary function tests

Indexed keywords

INSULIN; RECOMBINANT HUMAN INSULIN; ANTIDIABETIC AGENT;

ADULT; ARTICLE; CELL COUNT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES CONTROL; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LEUKOCYTE DIFFERENTIAL COUNT; LUNG FUNCTION; LUNG LAVAGE; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RESPIRATORY EPITHELIUM; RESPIRATORY TRACT INFLAMMATION; ADOLESCENT; BRONCHOSCOPY; CHEMISTRY; CYTOLOGY; INHALATIONAL DRUG ADMINISTRATION; LUNG FUNCTION TEST; MIDDLE AGED; PHASE 3 CLINICAL TRIAL;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; BRONCHOALVEOLAR LAVAGE FLUID; BRONCHOSCOPY; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; RESPIRATORY FUNCTION TESTS;

EID: 52749089075     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00129907     Document Type: Article

References (30)

1. Hollander PA, Blonde L, Rowe R, et al. Efficacy and safety of inhaled insulin (Exubera®) compared with subcutaneous insulin therapy in patients with type 2 diabetes: results of a 6-month, randomized, comparative trial. Diabetes Care 2004; 27: 2356-2362.
2. Quattrin T, Belanger A, Bohannon NJ, Schwartz SL. Efficacy and safety of inhaled insulin (Exubera®) compared with subcutaneous insulin therapy in patients with type 1 diabetes: results of a 6-month, randomized, comparative trial. Diabetes Care 2004; 27: 2622-2627.
3. Skyler JS, Jovanovic L, Klioze S, Reis J, Duggan W. Two-year safety and efficacy of inhaled human insulin (Exubera®) in adult patients with type 1 diabetes. Diabetes Care 2007; 30: 579-585.
4. Rosenstock J, Foyt H, Klioze S, Reis J, Duggan W. Inhaled human insulin (Exubera®) therapy shows sustained efficacy and is well tolerated over a 2-year period in patients with type 2 diabetes (T2DM). Diabetes 2006; 30: Suppl. 1, A26.
5. Rave K, Botts S, Heinemann L, et al. Time-action profile of inhaled human insulin in comparison with subcutaneously injected insulin lispro and regular human insulin. Diabetes Care 2005; 28: 1077-1082.
6. Teeter JG, Riese RJ. Dissociation of lung function changes with humoral immunity during inhaled human insulin therapy. Am J Respir Crit Care Med 2006; 173: 1194-1200.
7. Norwood P, Dumas M, Cefalu W, et al. Randomized study to characterize glycemic control and short-term pulmonary function in patients with type 1 diabetes receiving inhaled human insulin (Exubera®). J Clin Endocrinol Metab 2007; 22: 2211-2214.
8. Garg S, Rosenstock J, Silverman BL, et al. Efficacy and safety of preprandial human insulin inhalation powder versus injectable insulin in patients with type 1 diabetes. Diabetologia 2006; 49: 891-899.
9. Merchant RK, Schwartz DA, Helmers RA, Dayton CS, Hunninghake GW. Bronchoalveolar lavage cellularity: the distribution in normal volunteers. Am Rev Respir Dis 1992; 146: 448-453.
10. Costabel U, Guzman J. Bronchoalveolar lavage in interstitial lung disease. Curr Opin Pulm Med 2001; 7: 255-261.
11. Thompson AB, Huerta G, Robbins RA, et al. The bronchitis index: a semiquantitative visual scale for the assessment of airways inflammation. Chest 1993; 103: 1482-1488.
12. Liu MC, Hubbard WC, Proud D, et al. Immediate and late inflammatory responses to ragweed antigen challenge of the peripheral airways in allergic asthmatics: cellular, mediator, and permeability changes. Am Rev Respir Dis 1991; 144: 51-58.
13. Wise R, Teeter JG, Jensen RL, et al. Standardization of the single-breath diffusing capacity (DL,CO) in a multicenter clinical trial. Chest 2007; 132: 1191-1197.
14. The BAL Cooperative Group Steering Committee. Bronchoalveolar lavage constituents in healthy individuals, idiopathic pulmonary fibrosis, and selected comparison groups. Am Rev Respir Dis 1990; 141: S169-S202.
15. Ettensohn DB, Jankowski MJ, Duncan PG, Lalor PA. Bronchoalveolar lavage in the normal volunteer subject. I. Technical aspects and intersubject variability. Chest 1988; 94: 275-280.
16. Baughman R, Strohofer S, Kim CK. Variation of differential cell counts of bronchoalveolar lavage fluid. Arch Pathol Lab Med 1986; 110: 341-343.
17. Pingleton SK, Harrison GF, Stechschulte DJ, Wesselius LJ, Kerby GR, Ruth WE. Effect of location, pH, and temperature of instillate in bronchoalveolar lavage in normal volunteers. Am Rev Respir Dis 1983; 128: 1035-1037.
18. Velluti G, Capelli O, Lusuardi M, Braghiroli A, Azzolini L. Bronchoalveolar lavage in the normal lung. 2. Cell distribution and cytomorphology. Respiration 1984; 46: 1-7.
19. Lofdahl JM, Cederlund K, Nathell L, Eklund A, Skold CM. Bronchoalveolar lavage in COPD: fluid recovery correlates with the degree of emphysema. Eur Respir J 2005; 25: 275-281.
20. Liu MC, Bleecker ER, Lichtenstein LM, et al. Evidence for elevated levels of histamine, prostaglandin D2, and other bronchoconstricting prostaglandins in the airways of subjects with mild asthma. Am Rev Respir Dis 1990; 142: 126-132.
21. Wenzel SE, Szefler SJ, Leung DY, Sloan SI, Rex MD, Martin RJ. Bronchoscopic evaluation of severe asthma. Persistent inflammation associated with high dose glucocorticoids. Am J Respir Crit Care Med 1997; 156: 737-743.
22. Lommatzsch M, Julius P, Kuepper M, et al. The course of allergen-induced leukocyte infiltration in human and experimental asthma. J Allergy Clin Immunol 2006; 118: 91-97.
23. Fowler AA, Hyers TM, Fisher BJ, Bechard DE, Centor RM, Webster RO. The adult respiratory distress syndrome: cell populations and soluble mediators in the air spaces of patients at high risk. Am Rev Respir Dis 1987; 136: 1225-1231.
24. Samet JM, Hatch GE, Horstman D, et al. Effect of antioxidant supplementation on ozone-induced lung injury in human subjects. Am J Respir Crit Care Med 2001; 164: 819-825.
25. Balmes JR, Chen LL, Scannell C, et al. Ozone-induced decrements in FEV1 and FVC do not correlate with measures of inflammation. Am J Respir Crit Care Med 1996; 153: 904-909.
26. Devlin RB, McDonnell WF, Becker S, et al. Time-dependent changes of inflammatory mediators in the lungs of humans exposed to 0.4 ppm ozone for 2 hr: a comparison of mediators found in bronchoalveolar lavage fluid 1 and 18 hr after exposure. Toxicol Appl Pharmacol 1996; 138: 176-185.
27. Weinmann GG, Liu MC, Proud D, Weidenbach-Gerbase M, Hubbard W, Frank R. Ozone exposure in humans: inflammatory, small and peripheral airway responses. Am J Respir Crit Care Med 1995; 152: 1175-1182.
28. Holgate ST, Sandstrom T, Frew AJ, et al. Health effects of acute exposure to air pollution. Part I: Healthy and asthmatic subjects exposed to diesel exhaust. Res Rep Health Eff Inst 2003; 112: 1-30.
29. EXUBERA®. Summary of Product Characteristics. Kent, Pfizer Ltd, 2004.
30. Kurtzhals P, Schaffer L, Sorensen A, et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 2000; 49: 999-1005.